Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial.

Background: In the phase 3 JAVELIN Renal 101 trial (NCT02684006), first-line treatment with avelumab + axitinib resulted in significantly longer progression-free survival (PFS) and a higher objective response rate (ORR) vs sunitinib in patients with advanced renal cell carcinoma (aRCC). We report the final analysis, including the primary analysis of overall survival (OS).

Patients And Methods: Patients with untreated aRCC (any prognostic risk score) were enrolled.

[Not Available].

The aim of the work was to create a survey related to health questions to be distributed to associations active for trans* people's rights. 165 answers were obtained: among these, 45.6% are from trans* people and 31.

Resurgence of scabies in Italy: The new life of an old disease.

Scabies, an old parasitic disease with a worldwide presence, has witnessed a recent resurgence in many parts of the world even in the light of the COVID-19 pandemic. We conducted a study on this resurgence in the Italian province of Messina, Sicily, evaluating the general features of affected people to better understand the possible modes of transmission. Specifically, we considered all the scabies notifications made in the period 2003-2022.